The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic Millimeter

• Published in: The New England journal of medicine Vol. 335; no. 15; pp. 1091 - 1098
• Main Authors: Katzenstein, David A, Hammer, Scott M, Hughes, Michael D, Gundacker, Holly, Jackson, J. Brooks, Fiscus, Susan, Rasheed, Suraiya, Elbeik, Tarek, Reichman, Richard, Japour, Anthony, Merigan, Thomas C, Hirsch, Martin S
• Format: Journal Article
• Language: English
• Published: Boston, MA Massachusetts Medical Society 10.10.1996
• Subjects: Biological and medical sciences; Drug therapy; HIV; Human immunodeficiency virus; Immunity (Disease); Immunodeficiencies; Immunodeficiencies. Immunoglobulinopathies; Immunopathology; Medical sciences; Human; Immunopathology; Purine nucleoside; Treatment efficiency; Virological exploration; Biological marker; AIDS; Immune deficiency; Virology; Infection; Chemotherapy; Immunology; Immunological investigation; Viral disease; Dideoxynucleoside; Antiviral; Pyrimidine derivatives; Therapeutic protocol
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJM199610103351502

The AIDS Clinical Trials Group Study 175 (ACTG 175) provides direct evidence, in the clinical report elsewhere in this issue of the Journal, 1 of the clinical and immunologic benefits (e.g., increased CD4 cell counts) of the treatment of human immunodeficiency virus (HIV) infection with didanosine, zidovudine plus didanosine, and zidovudine plus zalcitabine, as compared with zidovudine monotherapy. Although changes in CD4 cell counts have provided a basis for the initiation of antiretroviral treatment and have been used to help define the acquired immunodeficiency syndrome (AIDS), 2 the plasma HIV RNA concentration is increasingly used as a measure of viral replication in . . .